Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for pioglitazone
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pioglitazone or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on pioglitazone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
The efficacy and safety of pioglitazone vs insulin treatment in type 2 diabetes mellitus: a systematic review and meta-analysis of randomised controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content
Effect of switching from pioglitazone to the sodium glucose co-transporter-2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type 2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison The effects of dapagliflozin (DAP) and pioglitazone (PIO) on body weight and glycaemic control were compared in patients with type 2 diabetes mellitus. Seventy-one patients on PIO were either switched to DAP (n = 36) at 5 mg per day
Heart Failure After Ischemic Stroke or TIA in Insulin-Resistant Patients Without Diabetes Treated with Pioglitazone The IRIS trial (Insulin Resistance Intervention After Stroke) demonstrated that pioglitazone reduced the risk for both cardiovascular events and diabetes mellitus in insulin-resistant patients. However, concern remains that pioglitazone may increase the risk for heart failure (HF) in susceptible individuals.In IRIS, patients with insulin resistance but without diabetes mellitus (...) were randomized to pioglitazone or placebo (1:1) within 180 days of an ischemic stroke or transient ischemic attack and followed for ≤5 years. To identify patients at higher HF risk with pioglitazone, we performed a secondary analysis of IRIS participants without HF history at entry. HF episodes were adjudicated by an external review, and treatment effects were analyzed using time-to-event methods. A baseline HF risk score was constructed from a Cox model estimated using stepwise selection
Combination of metformin and pioglitazone and its effect in treatment of comorbid pathology. Introduction: The early development and high incidence of cardiovascular lesion in patients with type 2 diabetes mellitus is one of the most serious challenges for the diabetology worldwide. The aim: The purpose of the paper is to determine the dynamics of the insulin resistance indices in patients with type 2 diabetes mellitus concomitant with coronary heart disease in the combination therapy (...) with metformin and pioglitazone during 3 and 6 months.Materials and methods: 95 patients with type 2 diabetes mellitus and coronary heart disease have been treated and randomized into two groups: the comparison group (n=37), treated with metformin and sulfonylureas, and the study group (n=58), treated with metformin in combination with pioglitazone. Prior, after 3 and 6 months of treatment C-peptide was assessed and index of the insulin resistance was calculated.Results: The resulting data proved
Pioglitazone Top results for pioglitazone - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for pioglitazone The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms
Anti-inflammatory and endothelium protective effect of long-term pioglitazone intake in patients suffering from bronchial asthma concurrent with ischemic heart disease. Treatment of co-morbidities, including bronchial asthma (BA) and coronary heart disease (CHD), is a relevant issue of modern therapy. The aim of the research is to study the impact of long-term intake of pioglitazone on the development of inflammation and ED in patients with BA concurrent with CHD.The clinical study involved 50 (...) people aged 40-75 who suffered from asthma concurrent with CHD. On the first day of the study, blood samples were collected and clinical examinations were performed, after which patients were randomized and divided into the control group who continued to receive only the standard therapy, and the study group, who received pioglitazone (Pioglar, Ranbaxy, India) 15 mg once a day along with comprehensive therapy. Re-examination was carried out in 6 months.It has been found that inclusion of pioglitazone
Effect of pioglitazone on insulin resistance, progression of atherosclerosis and clinical course of coronary heart disease. Pioglitazone, a medication of thiazolidinedione group, is capable of triggering the peroxisome proliferator-activated receptors (PPAR-γ). Activation of receptor PPAR-γ regulates carbohydrate and lipid metabolism, immune and inflammatory responses in heart tissues.Our aim was to study the effect of pioglitazone on insulin resistance, the clinical course of atherosclerosis (...) and coronary heart disease (CHD).The study included 43 patients with coronary artery disease. Patients were divided into the main group - 20 patients, in whom pioglitazone (Pioglar, Ranbaxy, India) was included in the combined therapy at a dose of 15 mg 1 time per day in the morning, and the comparison group - 23 patients receiving standard complex drug therapy over 6 months. Patients underwent clinical examination, ultrasound of neck vessels, study of carbohydrate and lipid metabolism.Joining pioglitazone
Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke) The IRIS trial (Insulin Resistance Intervention after Stroke) demonstrated that pioglitazone reduced the risk for a composite outcome of stroke or myocardial infarction among nondiabetic patients with insulin resistance and a recent stroke or transient ischemic attack. The current planned secondary (...) analysis uses updated 2013 consensus criteria for ischemic stroke to examine the effect of pioglitazone on stroke outcomes.Participants were randomly assigned to receive pioglitazone (45 mg/d target dose) or placebo within 180 days of a qualifying ischemic stroke or transient ischemic attack and were followed for a maximum of 5 years. An independent committee, blinded to treatment assignments, adjudicated all potential stroke outcomes. Time to first stroke event was compared by treatment group, overall
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Polycystic ovary syndrome (PCOS) is characterised by infrequent or absent ovulation, and high levels of androgens and insulin (hyperinsulinaemia). Hyperinsulinaemia occurs secondary to insulin resistance and is associated with increased risk of cardiovascular disease and diabetes mellitus. Insulin-sensitising agents such as metformin (...) ). We assessed statistical heterogeneity using the I2 statistic and reported quality of the evidence for primary outcomes using GRADE methodology.We assessed the interventions metformin, clomiphene citrate, metformin plus clomiphene citrate, D-chiro-inositol, rosiglitazone and pioglitazone. We compared these with each other, placebo or no treatment. We included 48 studies (4451 women), 42 of which investigated metformin (4024 women). Evidence quality ranged from very low to moderate. Limitations
Effects of pioglitazone on cognitive function in patients with a recent ischaemic stroke or TIA: a report from the IRIS trial Patients with cerebrovascular disease are at increased risk for cognitive dysfunction. Modification of vascular risk factors, including insulin resistance, could improve poststroke cognitive function.In the Insulin Resistance Intervention after Stroke (IRIS) trial, patients with a recent ischaemic stroke or transient ischaemic attack (TIA) were randomised to pioglitazone (...) at baseline and at least once during follow-up and were included in the analysis. Median 3MS score at baseline was 97 (IQR 93-99). The average overall least squared mean 3MS score increased by 0.27 in the pioglitazone group and by 0.29 in the placebo group (mean difference between treatment groups -0.02; 95% CI -0.33 to 0.28, p=0.88).Among insulin-resistant patients with a recent ischaemic stroke or TIA, pioglitazone did not affect cognitive function, as measured by the 3MS, over 5
Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: An RCT. Insulin resistance and hyperinsulinemia may play a role in pathogenesis of PCOS. One of the common therapeutic methods is using insulin-sensitizing drugs such as metformin and thiazolidinediones.The purpose was to determine the effect of metformin and pioglitazone on clinical, hormonal and metabolic parameters in women with PCOS.Eighty four women (...) randomly received one of the following for 3 months: metformin (n=28) (500 mg three times a day), pioglitazone (30 mg daily) (n=28) and combination of both metformin and pioglitazone (n=28) (30 mg/day pioglitazone plus 500 mg metformin three times a day). Hormonal profile, fasting serum insulin, body weight, body mass index, menstrual status and waist to hip ratio were evaluated before and after treatment.Metformin and pioglitazone and combination therapy induced favorable changes in fasting serum
Gamechanger? Can Pioglitazone Reduce Cardiovascular Events After a Stroke? An Analysis of the IRIS Trial Gamechanger? Can Pioglitazone Reduce Cardiovascular Events After a Stroke? An Analysis of the IRIS Trial – Clinical Correlations Search Gamechanger? Can Pioglitazone Reduce Cardiovascular Events After a Stroke? An Analysis of the IRIS Trial January 19, 2017 7 min read By Johanna Hase, MD Peer Reviewed Welcome to Gamechangers, a series that takes a critical look at the latest in medical (...) reduce her risk of another stroke. Assuming you are already managing her HLD and HTN, what are your options? Would a thiazolidinedione (pioglitazone) decrease her risk of stroke? Why does this matter? Even with optimal medical therapy, survivors of , and over 50% of non-diabetic . The Prospective Pioglitazone Clinical Trail in Macrovascular Events (PROactive) showed that in diabetics with cardiovascular disease, patients [3,4]. This is postulated to be due to its effects on the PPAR-γ and PPAR
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. 27532845 2016 08 18 2018 12 02 1533-4406 375 7 2016 08 18 The New England journal of medicine N. Engl. J. Med. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. 704 10.1056/NEJMc1605904 Viscoli Catherine M CM Kernan Walter N WN Young Lawrence H LH eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Hypoglycemic Agents 0 Thiazolidinediones AIM IM N Engl J Med. 2016 Apr 7;374(14):1321-31 26886418 N Engl
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. 27532846 2016 08 18 2018 12 02 1533-4406 375 7 2016 08 18 The New England journal of medicine N. Engl. J. Med. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. 702-3 10.1056/NEJMc1605904 Bursztyn Michael M Hadassah-Hebrew University Medical Center, Jerusalem, Israel firstname.lastname@example.org. eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Hypoglycemic Agents 0 Thiazolidinediones AIM IM N Engl J Med
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. 27532847 2016 08 18 2018 12 02 1533-4406 375 7 2016 08 18 The New England journal of medicine N. Engl. J. Med. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. 703 10.1056/NEJMc1605904 Doehner Wolfram W Charité Universitätsmedizin Berlin, Berlin, Germany email@example.com. Anker Stefan D SD University Medical Center Göttingen, Göttingen, Germany. eng Letter Comment United States N Engl J Med 0255562 0028
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. 27532848 2016 08 18 2018 12 02 1533-4406 375 7 2016 08 18 The New England journal of medicine N. Engl. J. Med. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. 703-4 10.1056/NEJMc1605904 Hu Kejia K Huashan Hospital, Shanghai, China firstname.lastname@example.org. Xu Wendong W Huashan Hospital, Shanghai, China email@example.com. Williams Ziv Z Massachusetts General Hospital, Boston, MA. eng Letter Comment United States N
Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries. To evaluate the association between pioglitazone use and bladder cancer risk in patients with type 2 diabetes. Retrospective cohort study using propensity score matched cohorts. Healthcare databases from Finland, the Netherlands, Sweden, and the United Kingdom. Data comprised country specific datasets of linked records on prescriptions, hospitals (...) , general practitioners, cancer, and deaths. Patients with type 2 diabetes who initiated pioglitazone (n=56 337) matched with patients with type 2 diabetes in the same country exposed to diabetes drug treatments other than pioglitazone (n=317 109). Two matched cohorts were created, using a 1:1 fixed ratio (nearest match cohort) and a 1:10 variable ratio (multiple match cohort). Patients were matched on treatment history and propensity scores accounting for several variables associated with pioglitazone
Pioglitazone (brand name: Actos) and bladder cancer: A new type "time-related bias" Page xvi · MED CHECK - TIP August 2016/ Vol.2 No.5 -The Informed Prescriber C N o 5 M ED HECK A u g u s t 2 0 1 6 Be careful with serious bias in epidemiologic studies Symptoms after HPV vaccine and "frailty exclusion bias" Actos (pioglitazone) and bladder cancer: "time-related bias" of a new type Editorial: Epidemiologists and biostatisticians, be honest ! Adverse Reactions Symptoms after HPV vaccine: Typical (...) "frailty exclusion bias" in Nagoya City study Critical comments from theoretical viewpoints Pioglitazone (brand name: Actos) and bladder cancer: A new type "time-related bias" CONTENTS (August 2016, Vol. 2, No. 5) 17 18 22 Volume 2 C M ED HECKMED CHECK - TIP August 2016 / Vol.2 No.5 · Page 17 Epidemiologists and biostatisticians, be honest! When new types of substances are introduced into medicine, an unfortunate result is new types of harm from new drugs. In Japan, we have experienced several serious
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized, Controlled Trial. The metabolic defects of nonalcoholic steatohepatitis (NASH) and prediabetes or type 2 diabetes mellitus (T2DM) seem to be specifically targeted by pioglitazone. However, information about its long-term use in this population is limited.To determine the efficacy and safety of long-term pioglitazone treatment in patients with NASH (...) and prediabetes or T2DM.Randomized, double-blind, placebo-controlled trial. (ClinicalTrials.gov: NCT00994682).University hospital.Patients (n = 101) with prediabetes or T2DM and biopsy-proven NASH were recruited from the general population and outpatient clinics.All patients were prescribed a hypocaloric diet (500-kcal/d deficit from weight-maintaining caloric intake) and then randomly assigned to pioglitazone, 45 mg/d, or placebo for 18 months, followed by an 18-month open-label phase with pioglitazone
Pioglitazone use and risk of bladder cancer: population based cohort study. To determine whether pioglitazone compared with other antidiabetic drugs is associated with an increased risk of bladder cancer in people with type 2 diabetes.Population based cohort study.General practices contributing data to the United Kingdom Clinical Practice Research Datalink.A cohort of 145,806 patients newly treated with antidiabetic drugs between 1 January 2000 and 31 July 2013, with follow-up until 31 July (...) 2014.The use of pioglitazone was treated as a time varying variable, with use lagged by one year for latency purposes. Cox proportional hazards models were used to estimate adjusted hazard ratios with 95% confidence intervals of incident bladder cancer associated with pioglitazone overall and by both cumulative duration of use and cumulative dose. Similar analyses were conducted for rosiglitazone, a thiazolidinedione not previously associated with an increased risk of bladder cancer.The cohort